{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:08:45Z","timestamp":1790784525330,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.fjurol.2026.103200","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:25:03Z","timestamp":1788996303000},"page":"103200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk stratification in non-muscle-invasive bladder cancer in the era of expanding therapeutic options: Are current classifications still adequate?"],"prefix":"10.1016","volume":"36","author":[{"given":"Igor","family":"Duquesne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Abou","family":"Chakra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"de la Taille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fjurol.2026.103200_bib0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.fjurol.2026.103200_bib0010","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103200_bib0015","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103200_bib0020","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 Amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103200_bib0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103200_bib0030","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1200\/JCO-25-01651","article-title":"TAR-200 for Bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study","volume":"43","author":"Daneshmand","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2026.103200_bib0035","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) Incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103200_bib0040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.euo.2021.11.006","article-title":"Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu\u00e9rin","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103200_bib0045","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s00261-022-03449-w","article-title":"Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) for the detection of muscle-invasive bladder cancer: a meta-analysis","volume":"47","author":"Feng","year":"2022","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.fjurol.2026.103200_bib0050","doi-asserted-by":"crossref","first-page":"102742","DOI":"10.1016\/j.fjurol.2024.102742","article-title":"French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0Update 2024\u20132026: non-muscle invasive bladder cancer (NMIBC)","volume":"34","author":"Roumigui\u00e9","year":"2024","journal-title":"Fr J Urol"},{"key":"10.1016\/j.fjurol.2026.103200_bib0055","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae Insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.fjurol.2026.103200_bib0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2026.103200_bib0065","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.fjurol.2026.103200_bib0070","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2026.103200_bib0075","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103200_bib0080","doi-asserted-by":"crossref","first-page":"273.e11","DOI":"10.1016\/j.urolonc.2022.01.008","article-title":"Variant histologies in bladder cancer: does the centre have an impact in detection accuracy?","volume":"40","author":"Cimadamore","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103200_bib0085","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.fjurol.2026.103200_bib0090","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.euo.2025.08.003","article-title":"Intermediate-risk non-muscle-invasive bladder cancer: recommendations for definitions, risk stratification, management strategies, and clinical trial design from the International Bladder Cancer Group","volume":"8","author":"Li","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103200_bib0095","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.euo.2024.09.011","article-title":"Clinical implementation of urinary biomarkers for surveillance of non-muscle-invasive bladder cancer (NMIBC): considerations from the European Association of Urology NMIBC Guideline Panel","volume":"8","author":"Liedberg","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103200_bib0100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","article-title":"ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)","volume":"37","author":"Roupret","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.fjurol.2026.103200_bib0105","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.fjurol.2026.103200_bib0110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.36469\/jheor.2024.124208","article-title":"Adherence to first-line intravesical Bacillus Calmette-Gu\u00e9rin therapy in the context of guideline recommendations for US patients with high-risk non-muscle invasive bladder cancer","volume":"11","author":"Gaylis","year":"2024","journal-title":"J Health Econ Outcomes Res"},{"key":"10.1016\/j.fjurol.2026.103200_bib0115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.urolonc.2021.11.008","article-title":"Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) in suspected muscle invasive bladder cancer: a systematic review and diagnostic meta-analysis","volume":"40","author":"Jazayeri","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103200_bib0120","first-page":"e99197","article-title":"Pitfalls and limitations of the vesical imaging-reporting and data system (VI-RADS): challenges in the multiparametric magnetic resonance imaging (mpMRI) assessment of bladder cancer","volume":"17","author":"Laert","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.fjurol.2026.103200_bib0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/genes17020153","article-title":"Genomic subtypes and computational biomarkers in non-muscle-invasive bladder cancer guiding optimal timing of radical cystectomy and BCG response prediction","volume":"17","author":"Schi\u021bcu","year":"2026","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.fjurol.2026.103200_bib0130","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.euf.2024.08.008","article-title":"Patient-derived organoids in bladder cancer: opportunities and challenges","volume":"11","author":"Radi\u0107","year":"2025","journal-title":"Eur Urol Focus"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026001312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026001312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:37:22Z","timestamp":1790782642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393026001312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2950393026001312"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103200","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk stratification in non-muscle-invasive bladder cancer in the era of expanding therapeutic options: Are current classifications still adequate?","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103200"}}